Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Marker Therapeutics Reports Q2 2022 Operating and Financial Results


HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

“We are proud of our progress this year in advancing our Company-sponsored clinical program in AML, and early results support the ability of MT-401, a multiTAA-specific T cell product, to drive results for patients with AML,” said Peter L. Hoang, Marker’s President and Chief Executive Officer. “This quarter, we continued to dose patients in the Phase 2 AML study, and we expect to provide a topline readout of active disease patients in Q3 2022. The recent $8 million upfront cash payment to Marker by Wilson Wolf has aided the efficient execution of Marker’s programs.”

Mr. Hoang continued: “In addition, we recently announced that FDA cleared our IND investigating the safety and efficacy of MT-601 in patients with relapsed/refractory lymphoma, and that we are on track to file another IND by year-end to investigate the safety and efficacy of MT-601 in patients with pancreatic cancer, which has already received FDA Orphan Drug Designation. We anticipate dosing the first patients in these trials, in addition to dosing patients in our off-the-shelf therapy for AML, next year.”

“We are very optimistic about the ability of MT-401 to drive results for patients with measurable residual disease given the results we have seen to date in the ARTEMIS study,” said Dr. Mythili Koneru, Marker’s Chief Medical Officer. “Of note, we were very pleased to note that the second patient we treated with MRD+ disease was found to be MRD- by that patient’s week 8 follow-up. The ability to administer MT-401 without the need for lymphodepletion, coupled with our improved accelerated manufacturing process, enable us to treat patients who have MRD+ disease. We believe that the results observed to date support the notion that patients with AML would have meaningful benefit from a multi-antigen targeted T cell therapy approach.”


Acute Myeloid Leukemia (MT-401)

  • Marker has enrolled 13 evaluable patients in total, including 6 in the Safety Lead-in cohorts.
  • 5 patients have been treated with MT-401 manufactured by a revised process and have completed dose-limiting toxicity (DLT) periods with no DLTs reported.
  • One additional MRD+ patient was treated and became MRD- at 8 weeks after the first infusion.
  • Marker remains on track to dose the first patient in 2023 with MT-401-OTS, a scalable, off-the-shelf product candidate with the potential to match patients to treatment in under three days. The Company is in the process of developing a patient cell bank inventory.

Lymphoma (MT-601)

  • On August 4, 2022, Marker announced that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug (IND) application for MT-601, a multi-tumor-associated antigen (multiTAA)-specific T cell product targeting six antigens, for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.
  • Marker expects to initiate a Phase 1 trial in 2023.

Pancreatic Cancer (MT-601)

  • Marker is on track to file an IND for MT-601 for the treatment of pancreatic cancer in 2022.
  • The Company intends to initiate a Phase 1 multicenter study of MT-601 administered in combination with front-line chemotherapy to patients with locally advanced unresectable or metastatic pancreatic cancer in 2023.


  • Cash Position and Guidance: At June 30, 2022, Marker had cash and cash equivalents of $25.8 million.
  • R&D Expenses: Research and development expenses were $6.6 million for the quarter ended June 30, 2022, compared to $7.4 million for the quarter ended June 30, 2021.
  • G&A Expenses: General and administrative expenses were $3.5 million for the quarter ended June 30, 2022, compared to $3.6 million for the quarter ended June 30, 2021.
  • Net Loss: Marker reported a net loss of $9.2 million for the quarter ended June 30, 2022, compared to a net loss of $10.9 million for the quarter ended June 30, 2021.

Organizational Restructuring

On August 10, 2022, the Company implemented changes to the Company’s organizational structure as part of an operational cost reduction plan to conserve the Company’s available capital. In connection with these changes, the Company reduced headcount in its general and administrative function by approximately 23.5%, including the separation of the Company’s Chief Financial Officer. The Company estimates that the severance and termination-related costs will total approximately $0.7 million and will be recorded in the third quarter of 2022. The Company expects that the payment of these costs will be substantially complete in September of 2023.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit:

Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials of our product candidates; our ability to use our manufacturing facilities to support clinical and commercial demand; and our future operating expenses and capital expenditure requirements. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Marker Therapeutics, Inc.
Condensed Consolidated Balance Sheets

June 30, December 31,
2022 2021
Current assets:
Cash and cash equivalents $ 25,821,708 $ 42,351,145
Restricted cash - 1,146,186
Prepaid expenses and deposits 2,826,699 2,484,634
Other receivables 627,629 237
Total current assets 29,276,036 45,982,202
Non-current assets:
Property, plant and equipment, net 13,740,158 10,096,861
Construction in progress - 2,225,610
Right-of-use assets, net 9,303,544 9,830,461
Total non-current assets 23,043,702 22,152,932
Total assets $ 52,319,738 $ 68,135,134
Current liabilities:
Accounts payable and accrued liabilities $ 4,735,251 $ 11,134,913
Related party deferred revenue 8,000,000 -
Lease liability 738,389 620,490
Deferred revenue - 1,146,186
Total current liabilities 13,473,640 12,901,589
Non-current liabilities:
Lease liability, net of current portion 10,819,825 11,247,950
Total non-current liabilities 10,819,825 11,247,950
Total liabilities 24,293,465 24,149,539
Stockholders' equity:
Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively - -
Common stock, $0.001 par value, 300 million and 150 million shares authorized, 83.6 million and 83.1 million shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively 83,599 83,079
Additional paid-in capital 445,215,725 442,020,871
Accumulated deficit (417,273,051 ) (398,118,355 )
Total stockholders' equity 28,026,273 43,985,595
Total liabilities and stockholders' equity $ 52,319,738 $ 68,135,134

Marker Therapeutics, Inc.
Condensed Consolidated Statements of Operations

For the Three Months Ended For the Six Months Ended
June 30, June 30,
2022 2021 2022 2021
Grant income $ 790,508 $ - $ 1,754,830 $ -
Total revenues 790,508 - 1,754,830 -
Operating expenses:
Research and development $ 6,555,299 $ 7,350,035 13,581,365 12,993,064
General and administrative 3,515,183 3,559,150 7,248,184 6,697,108
Total operating expenses 10,070,482 10,909,185 20,829,549 19,690,172
Loss from operations (9,279,974 ) (10,909,185 ) (19,074,719 ) (19,690,172 )
Other income (expenses):
Arbitration settlement - - (118,880 ) -
Interest income 35,786 2,403 38,903 3,940
Net loss per share, basic and diluted $ (0.11 ) $ (0.13 ) $ (0.23 ) $ (0.28 )
Weighted average number of common shares outstanding, basic and diluted 83,592,043 83,030,470 83,351,184 69,823,729

Marker Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows

For the Six Months Ended
June 30,
2022 2021
Cash Flows from Operating Activities:
Net loss $ (19,154,696 ) $ (19,686,232 )
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization 1,156,113 1,032,971
Stock-based compensation 3,131,801 3,029,125
Amortization on right-of-use assets 517,059 504,232
Changes in operating assets and liabilities: -
Prepaid expenses and deposits (342,065 ) (743,876 )
Other receivables (627,392 ) 1,000,273
Accounts payable and accrued expenses (4,255,034 ) 108,230
Related party deferred revenue 8,000,000 -
Deferred revenue (1,146,186 ) -
Lease liability (300,368 ) (130,503 )
Net cash used in operating activities (13,020,768 ) (14,885,780 )
Cash Flows from Investing Activities:
Purchase of property and equipment (1,229,298 ) (842,048 )
Purchase of construction in progress (3,489,130 ) (958,965 )
Net cash used in investing activities (4,718,428 ) (1,801,013 )
Cash Flows from Financing Activities:
Proceeds from issuance of common stock, net 63,573 52,552,758
Proceeds from exercise of stock options - 3,087
Net cash provided by financing activities 63,573 52,555,845
Net (decrease) increase in cash, cash equivlants and restricted cash (17,675,623 ) 35,869,052
Cash, cash equivalents and restricted cash at beginning of the period 43,497,331 21,352,382
Cash, cash equivalents and restricted cash at end of the period $ 25,821,708 $ 57,221,434

Investors and Media Contacts

Marker Therapeutics:

Neda Safarzadeh
Vice President/Head of Investor Relations, PR & Marketing
(713) 400-6451

Solebury Trout:

Amy Bonanno

Primary Logo